GlassScriptPhysician profile
Michael J Kaminski
NPI 1134121130
$1,745.90
in general payments reported to CMS, 2019-2025
20 companies · $46.11 in 2025
The $46.11 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $185 · 2021: $239 · 2022: $149 · 2025: $46.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $46.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $46.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $458.70 | 2019-2022 | |
| Amgen INC. | $229.96 | 2019-2021 | |
| Biogen, INC. | $181.63 | 2019 | |
| Alexion Pharmaceuticals, INC. | $176.01 | 2019 | |
| Novo Nordisk INC | $98.59 | 2019-2021 | |
| Tanabe Pharma America, INC. | $94.92 | 2019 | |
| Genentech USA, INC. | $82.57 | 2019-2020 | |
| Daiichi Sankyo INC. | $75.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.39 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $47.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $33.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.08 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $24.93 | 2019-2021 | |
| Abbvie INC. | $24.56 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $21.55 | 2025 | Briviact |
| Sunovion Pharmaceuticals INC. | $19.96 | 2020 | |
| Allergan, INC. | $14.23 | 2019 | |
| Vistapharm, INC. | $13.62 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaminski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.